Metropolis Healthcare opened lower at ₹538.00, compared with its previous close of ₹538.55. During today's session, the stock has traded between ₹530.30 and ₹543.15, with an average traded price of ₹537.04. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Metropolis Healthcare is now worth
₹ 7,679.00
resulting in a loss of
₹ 2,321.00 (23.21%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-3.80 (-0.71%)
Day High
₹543.15
Day Low
₹530.30
Day Open
₹538.00
Prev Close
₹538.55
Volume
2,86,773
Value Traded
₹15.40 Cr
1W Return
-3.40%
1M Return
-8.67%
3M Return
-5.85%
6M Return
14.24%
1Y Return
7.22%
Market Cap (₹ Cr.)
11,090
PE Ratio
55.00
PB Ratio
7.42
Dividend Yield
0.93%
ROE
12.54%
ROCE
15.73%
Book Value (₹)
72.41
Face Value (₹)
2.00
EPS (TTM)
2.73
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-3.40%
6 Week
-
1 Month
-8.67%
3 Month
-5.85%
9 Month
14.07%
Metropolis Healthcare Q2FY27 Results: Revenue rises 15% YoY on volume growth
Revenue rose 15% YoY in Q2FY27. Growth driven by double-digit patient and test volume increases. TruHealth Wellness and Specialty segments were fastest-growing. EBITDA margins expanded on both YoY and QoQ basis.
7 days agoMetropolis Healthcare subsidiary MQSPL holds 54.90% stake in MedSource
Metropolis Healthcare's subsidiary MQSPL has partnered with MedSource. MQSPL holds a 54.90% stake in MedSource following a conversion. The transaction establishes MQSPL as a majority stakeholder in MedSource.
1mo agoFranklin Templeton raises stake in Metropolis Healthcare to 5.1%
Franklin Templeton Mutual Fund acquired 7,42,409 shares of Metropolis Healthcare. Total stake rose from 4.742% to 5.1% following the open market purchase. Acquisition executed entirely via Franklin India Opportunities Fund. Other Franklin Templeton schemes maintained unchanged holdings. Transaction disclosed under SEBI SAST Regulations on September 7, 2026.
1mo agoMetropolis Healthcare Latest Results: targets ₹2,500 crore organic revenue in three-year plan
Metropolis Healthcare has set a target of ₹2,500 crore in annual organic revenue. The target is part of a three-year strategic plan. The growth strategy is focused on organic expansion within the diagnostics business.
1mo agoMetropolis Healthcare uploads audio recording of Aug 27 investor meet
Metropolis Healthcare uploaded audio recording of Aug 27 investor meet. Group interaction held at 4:00 pm IST with analysts and investors. Discussions restricted to publicly available information per SEBI norms. Notice issued under Regulation 30 of SEBI LODR Regulations, 2015.
1mo agoMetropolis Healthcare transfers EQAS division to subsidiary for ₹1.25 crore
Metropolis Healthcare transferred its EQAS Division to subsidiary MQSPL. The slump sale consideration was ₹1.25 crore. Payment was made via issuance of MQSPL equity shares. The transfer became effective on August 27, 2026. Operations are now carried out by the subsidiary as a going concern.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,910.60 | -3.00% | ₹32,069.20 | 60.51 | +23.39% | |
| ₹1,406.50 | -3.14% | ₹14,486.63 | 79.85 | +43.37% | |
| ₹499.45 | -3.00% | ₹7,949.51 | 46.60 | +18.54% | |
| ₹620.95 | +0.23% | ₹6,244.21 | 73.19 | +31.77% | |
| ₹532.70 | +0.05% | ₹1,728.01 | 17.74 | -35.43% | |
| ₹314.40 | +1.88% | ₹1,637.42 | 45.94 | +7.80% | |
| ₹1,519.60 | -5.58% | ₹1,304.22 | 24.59 | +16.72% | |
| ₹549.85 | +0.95% | ₹1,074.57 | 14.50 | -2.73% | |
| ₹283.00 | -0.35% | ₹900.24 | -34.71 | -8.71% | |
| ₹105.19 | -0.40% | ₹765.65 | 33.11 | +31.06% | |
| ₹232.55 | +0.24% | ₹568.63 | 22.52 | -19.25% | |
| ₹64.50 | +0.00% | ₹81.09 | 16.62 | -33.30% |
An investment of ₹10,000 made 5 years ago in Metropolis Healthcare is now worth
₹ 7,679.00
resulting in a loss of
₹ 2,321.00 (23.21%)
Note: Past profits do not guarantee future returns.
